NYMX Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 54.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Nymox Pharmaceutical Insider Trading History Chart

This chart shows the insider buying and selling history at Nymox Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Nymox Pharmaceutical Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 07/6/2023 05:00 PM ET

This chart shows the closing price history over time for NYMX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Nymox Pharmaceutical Insider Trading History

See Full Table

SEC Filings (Institutional Ownership Changes) for Nymox Pharmaceutical (NASDAQ:NYMX)

1.14% of Nymox Pharmaceutical stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at NYMX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4$0Total InflowsTotal Outflows
Nymox Pharmaceutical logo
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Read More on Nymox Pharmaceutical

Today's Range

Now: N/A

50 Day Range

MA: $0.34
Low: $0.19
High: $0.47

52 Week Range

Now: N/A

Volume

932,700 shs

Average Volume

94,622 shs

Market Capitalization

$18.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64